Adial Pharmaceuticals (NASDAQ:ADIL – Get Free Report) announced its earnings results on Tuesday. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.23, Zacks reports.
Adial Pharmaceuticals Price Performance
ADIL stock opened at $0.77 on Thursday. Adial Pharmaceuticals has a one year low of $0.70 and a one year high of $3.10. The company’s 50 day moving average price is $0.90 and its two-hundred day moving average price is $0.99.
Analyst Upgrades and Downgrades
ADIL has been the subject of a number of research analyst reports. Rodman & Renshaw initiated coverage on shares of Adial Pharmaceuticals in a report on Thursday, November 14th. They set a “buy” rating and a $8.00 price objective for the company. RODMAN&RENSHAW raised Adial Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, November 14th.
About Adial Pharmaceuticals
Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.
Featured Stories
- Five stocks we like better than Adial Pharmaceuticals
- 3 Fintech Stocks With Good 2021 Prospects
- Eli Lilly Pours $27B Into U.S. Growth—What It Means for Investors
- Consumer Staples Stocks, Explained
- Why Now Might Be the Best Time to Buy Target Stock
- Insider Trading – What You Need to Know
- Why TJX Companies Belongs in Every Dividend Growth Portfolio
Receive News & Ratings for Adial Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adial Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
